What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
The Latest on: Engineered cancer cells
via Google News
The Latest on: Engineered cancer cells
- CRISPR technology creates pluripotent stem cells that are 'invisible' to the immune system on February 18, 2019 at 10:17 am
Unfortunately, these immunosuppressants leave patients more susceptible to infection and cancer," explained Professor of Surgery ... "This is the first time anyone has engineered cells that can be uni... […]
- CRISPR Gene Editing Makes Stem Cells ‘Invisible’ to Immune System on February 18, 2019 at 8:37 am
Human heart muscle cells derived from triple-engineered stem cells that are “invisible ... Unfortunately, these immunosuppressants leave patients more susceptible to infection and cancer,” explained P... […]
- Qatar Cancer Society takes part in 1st workshop on cell therapy on February 16, 2019 at 4:00 pm
Qatar Cancer Society (QCS) participated in Qatar’s first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI) held at Sidra Medicine on February 15-16. The workshop, organ... […]
- Cell-Cell Communication in The Tumor Microenvironment on February 15, 2019 at 8:56 am
Another very promising immune therapy approach involves the development of immune cells that are engineered to target proteins that are present on cancer cells. CAR T-cells and also CAR NK [natural ki... […]
- Wife of top Trump official claims measles ‘keep you healthy,’ ‘fight cancer’ on February 15, 2019 at 4:39 am
Knowing this, the researchers genetically engineered their own measles virus to sic on the patients’ cancer cells. Now, to call these engineered cells “measles” would be irresponsible. The measles vir... […]
- Researchers characterize mechanism of action of CAR T cells on February 14, 2019 at 9:34 am
adding a special receptor called a CAR that recognizes cancer cells. The genetically engineered cells are allowed to grow and multiply in the laboratory, and then sent back to the clinic to be ... […]
- TCR²’s IPO Raises $75M to Bring Cancer Cell Therapy to Solid Tumors on February 14, 2019 at 7:58 am
... engineering a patient’s own T cells to recognize cancer cells. The cells are then infused back into the patient. When these engineered T cells bind to cancer cells, they trigger a signaling ... […]
- Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC on February 14, 2019 at 3:57 am
Ovarian cancer (OvCa) exhibits a specific predilection ... omental adipocytes from Sparc knockout mice, genetically engineered human omental adipocytes in 3D co-cultures with OvCa cells, as well as tr... […]
- A killer sidekick for antitumor T cells on February 13, 2019 at 11:14 am
Engineered NK cells kill myeloid-derived suppressor cells ... Nonetheless, chimeric NKs may represent a broadly applicable strategy to improve CAR-T therapy and other T cell–based cancer treatments. […]
via Bing News